CREG1

Across TCGA pan-cancer cohorts, CREG1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CREG1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CREG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CREG1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where CREG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.295	0.912	.003	52	view →
UCEC	DFS	Median	II,III,IV	0.489	0.887	.006	30	view →
PDAC	OS	Tertile	II,III,IV	0.697	1.000	.010	10	view →
LSCC	DFS	Median	II,III,IV	0.910	0.649	.008	6	view →
HNSC	DFS	Median	III,IV	0.861	0.707	.024	3	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CREG1–LUAD (OS)

Open the LUAD breakdown →